Navigation Links
Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain
Date:9/23/2011

result in overdose and death.Summary of Clinical StudyPatients evaluated in this randomized, double-blind, double-dummy active controlled, superiority study had moderate-to-severe low back pain for at least three months and were receiving treatment with opioid analgesics at doses between 30 to 80 mg of morphine sulfate or the equivalent at least four days per week for at least 30 days prior to the screening visit.  Sixty-two percent (62%) of patients were taking hydrocodone-containing medications; 21% were taking oxycodone-containing medications; and 12% of patients were taking propoxyphene-containing medications.  Prospective patients were excluded if they were currently using the fentanyl transdermal-system, extended-release hydromorphone, or more than 80 mg per day of oral morphine equivalent for pain control upon entry into the study.

The study employed an enriched design – allowing only patients who both tolerated and responded to Butrans during an open label run-in period to enter into the 12-week double-blind phase of the trial, mimicking the treatment of patients in a clinical practice setting.  

The efficacy and safety of Butrans 20 mcg/hour was assessed using Butrans 5 mcg/hour as the low-dose control group.  All patients wore either active or placebo patches (double-dummy technique).  The study was performed at 75 centers in the United States.

Of the 1160 patients that entered the open-label run-in period, 57% were able to titrate to and tolerate the adverse effects of Butrans 20 mcg/hour and were randomized into a 12-week double-blind treatment phase.  Twelve percent (12%) of patients discontinued due to an adverse event and 21% discontinued due to lack of a therapeutic effect during the open-label titration period. A total of 660 patients were randomized to the double-blind phase to receive Butrans 20 mcg/hour, Butrans 5 mcg/hour, or an active control, for 12 weeks.  During the double-blind t
'/>"/>

SOURCE Purdue Pharma L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AIMs Program for Improving Echocardiography Appropriateness Yields Impressive Results
2. Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results
3. Accuray Announces Results for Fourth Quarter and Fiscal Year 2011
4. Misonix Schedules Fourth Quarter and Year-End Fiscal 2011 Financial Results Conference Call; September 20, 2011 at 4:30 p.m. Eastern
5. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
6. Pro-Dex, Inc. Announces Fiscal 2011 Fourth Quarter and Full-Year Results
7. Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
9. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
10. Innocoll Announces Top-line Results from its Phase 2 Clinical Trial Investigating XaraColl® for the Management of Post-operative Pain and Receives "Notice of Allowability" for XaraColl U.S. Patent Application
11. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Evolve Medical Clinics, the first ... urgent care arena, is having its Grand Opening ... health fair the clinic is sponsoring. Evolve offers ... patients in achieving high quality, convenient medical care. ... is a groundbreaking change in healthcare. The membership ...
(Date:9/2/2014)... September 02, 2014 Last year, SIGVARIS ... with the launch of a luxurious line of graduated compression ... the SEA ISLAND COTTON Socks are joining the SIGVARIS MEDICAL ... more people the comfort of natural cotton fibers. , ... are surprised to find socks as soft as the finest ...
(Date:9/2/2014)... Ticket Down is a reputable source ... September will be an exciting week for soccer fans in ... Ecuador and Bolivia will battle on U.S. soil in friendly ... September 5th - September 9th: , Brazil vs. Ecuador ... Mexico vs. Chile Tickets at Levi's Stadium on ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2
... developed countries seem to be becoming ever more hectic. With ... reveals that Australian children in the 10-15 year age ... every nigth when compared with just one generation ago. ... television watching are to blame, with adolescents no longer adhering ...
... alcohol will be introduced in England to ward-off people from ... your limits and drink responsibly will be out by the ... ministers and industry. ,The agreement was first planned ... proper format has been adopted. ,Ministers have insisted ...
... extracted from the blood of bird flu survivors have helped ... virus. ,Scientists have long suspected that culling immune-system ... hard-to-treat H5N1 flu strain. ,If the research pans ... immune system's search-and-destroy force, as an additional way to treat ...
... by an American researcher has revealed that bricks made from ... might be safer than predicted. ,Rather than leach ... bricks do the reverse, pulling minute amounts of the toxic ... Henry Liu, a longtime National Science Foundation (NSF) awardee and ...
... tobacco industry for spreading untruths about smoking in public places ... bans around the world. ,The WHO said ... about the health risks and dangers of second-hand tobacco smoke ... ,"We all know that smoking kills," Shigeru Omi, director of ...
... inflammation are more likely to later develop Alzheimer's disease ... to a study published in the May 29, 2007, ... Academy of Neurology. ,The study, which is ... healthy people with an average age of 79. Blood ...
Cached Medicine News:Health News:Australian Children Sleep Less, Perhaps Not Well Monitored 2Health News:UK Introduce New Health Warnings Against Alcohol 2Health News:Blood from Bird Flu Survivors Provides Breakthrough in Treatment of H5N1 2Health News:Fly Ash Bricks are Absolutely Safer Than Actually Predicted 2Health News:WHO Condemns Tobacco Industry for Misleading Public 2
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used with permanent pacing leads....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... the Tupos LV/A+, the single-lead principle has been ... time. The complete system, which consists of the ... minimizes the scope of surgery and the risk ... atrium and the ventricle via a single lead. ...
Medicine Products: